NEU.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 08:10):
Our systems believe the stock currently is undervalued by 0.26% compare to its pairs and should correct upwards.

Stats
Dagens volum	307 770
Gjennomsnittsvolum	420 507
Markedsverdi	2.58B
EPS	$0.860 ( Q4 \| 2023-12-31 )
Neste inntjeningsdato	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	16.84 (Sector) 0 (Industry) 0
ATR14	$0.0170 (0.08%)

ACW.AX 4.84%

ADO.AX 5.00%

AGH.AX 4.35%

ANP.AX -4.92%

ATH.AX 25.00%

AVE.AX -33.33%

BIT.AX 2.63%

BNO.AX -10.00%

BOT.AX -8.70%

CAN.AX 7.14%

CPH.AX 0.00%

CSL.AX -0.88%

CTE.AX 0.81%

CUV.AX -0.65%

CYP.AX 0.00%

DXB.AX 3.92%

ECS.AX 5.88%

EOF.AX -6.67%

GSS.AX 5.56%

IDT.AX -4.55%

IMC.AX -5.68%

IMM.AX 5.08%

IMU.AX -3.51%

IXC.AX 0.00%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX 5.26%

MSB.AX 1.01%

MVP.AX -2.47%

MXC.AX 2.44%

NEU.AX -4.98%

NOX.AX 0.00%

NSB.AX 0.00%

OCC.AX 2.82%

OPT.AX -1.43%

OSL.AX 25.00%

PAA.AX 0.00%

PAB.AX 14.29%

PAR.AX 13.73%

PBP.AX 0.00%

PIQ.AX -1.14%

PTX.AX 5.26%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX -0.27%

RCE.AX 5.26%

SPL.AX -3.16%

TLX.AX -3.00%

VBS.AX -1.30%

Korrelasjon (AI algo v.1.1b): Undervalued: 0.26% $20.31 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: 0.36 (neutral)

Signal:(43.663) Neutral

Neuren Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neuren Pharmaceuticals Korrelasjon - Valuta/Råvare

0.55
( weak )

0.53
( weak )

0.00
( neutral )

0.61
( weak )

0.00
( neutral )

0.19
( neutral )

Neuren Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$231.93M
Bruttogevinst:	$205.17M (88.47 %)
EPS:	$1.240

FY	2023
Omsetning:	$231.93M
Bruttogevinst:	$205.17M (88.47 %)
EPS:	$1.240

FY	2022
Omsetning:	$14.55M
Bruttogevinst:	$14.54M (99.93 %)
EPS:	$0.00150

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0728

Financial Reports:

No articles found.

Neuren Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.